N-[叔丁氧羰基]-N-(苯基甲基)-L-丙氨酸 | 159999-80-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-[叔丁氧羰基]-N-(苯基甲基)-L-丙氨酸
• 英文名称: Boc-N(Bzl)Ala-OH
• 英文别名: N-benzyl-N-Boc-L-alanine；(2S)-2-{benzyl[(tert-butoxy)carbonyl]amino}propanoic acid；(S)-2-(Benzyl(tert-butoxycarbonyl)amino)propanoic acid；(2S)-2-[benzyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]propanoic acid
• CAS: 159999-80-1
• 化学式: C₁₅H₂₁NO₄
• 分子量: 279.336
• InChiKey: MYGPVQDUOSMACR-NSHDSACASA-N

物化性质

• 沸点：
  416.0±34.0 °C(Predicted)
• 密度：
  1.146±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  66.8
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  N-[叔丁氧羰基]-N-(苯基甲基)-L-丙氨酸 在 2-乙氧基-1-乙氧碳酰基-1,2-二氢喹啉 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 38.0h， 生成 (S)-N-Benzyl-2-benzylamino-N-((S)-1-{benzyl-[(S)-1-(benzyl-trimethylsilanylmethyl-carbamoyl)-ethyl]-carbamoyl}-ethyl)-propionamide
  参考文献：
  名称：

  A Synthetic Strategy for the Preparation of Cyclic Peptide Mimetics Based on SET-Promoted Photocyclization Processes

  摘要：

  A novel method for the synthesis of cyclic peptide analogues has been developed. The general approach relies on the use of SET-promoted photocyclization reactions of peptides that contain N-terminal phthalimides as light absorbing electron acceptor moieties and C-terminal alpha-amidosilane or alpha-amidocarboxylate centers. Prototypical substrates are prepared by coupling preformed peptides with the acid chloride of N-phthalimidoglycine. Irradiation of these substrates results in the generation of cyclic peptide analogues in modest to good yields. The chemical efficiencies of these processes are not significantly affected by (1) the lengths of the peptide chains separating the phthalimide and alpha-amidosilane or alpha-amidocarboxylate centers and (2) the nature of the penultimate cation radical a-heterolytic fragmentation process (i.e., desilylation vs decarboxylation). An evaluation of the effects of N-alkyl substitution on the amide residues in the peptide chain showed that N-alkyl substitution does not have a major impact on the efficiencies of the photocyclization reactions but that it profoundly increases the stability of the cyclic peptide.

  DOI：

  10.1021/ja030297b
• 作为产物：
  描述：

  二碳酸二叔丁酯 在 sodium hydroxide 、 sodium hydride 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 水 为溶剂， 反应 60.5h， 生成 N-[叔丁氧羰基]-N-(苯基甲基)-L-丙氨酸
  参考文献：
  名称：

  WO2008/125945

  摘要：

  公开号：

文献信息

• Visible-Light-Mediated Decarboxylative Radical Additions to Vinyl Boronic Esters: Rapid Access to γ-Amino Boronic Esters
  作者：Adam Noble、Riccardo S. Mega、Daniel Pflästerer、Eddie L. Myers、Varinder K. Aggarwal

  DOI：10.1002/anie.201712186

  日期：2018.2.19

  The synthesis of alkyl boronic esters by direct decarboxylative radical addition of carboxylic acids to vinyl boronic esters is described. The reaction proceeds under mild photoredox catalysis and involves an unprecedented single-electron reduction of an α-boryl radical intermediate to the corresponding anion. The reaction is amenable to a diverse range of substrates, including α-amino, α-oxy, and

  描述了通过将羧酸直接脱羧基加成到乙烯基硼酸酯上来合成烷基硼酸酯。该反应在温和的光氧化还原催化下进行，涉及α-硼基自由基中间体前所未有的单电子还原成相应的阴离子。该反应适用于多种底物，包括α-氨基、α-氧基和烷基羧酸，从而提供了一种快速获取具有潜在生物学重要性的含硼分子的新方法。
• Analogues of Neurohypophyseal Hormones, Oxytocin and Arginine Vasopressin, Conformationally Restricted in the N-Terminal Part of the Molecule
  作者：Wioleta Kowalczyk、Adam Prahl、Izabela Derdowska、Dariusz Sobolewski、Jadwiga Olejnik、Janusz Zabrocki、Lenka Borovicková、Jiřina Slaninová、Bernard Lammek

  DOI：10.1021/jm058038f

  日期：2006.3.1

  generally accepted that the conformation of the N-terminal part of neurohypophyseal hormones analogues is important for their pharmacological activity. In this work, we decided to investigate how the substitution of positions 2 and 3 with the ethylene-bridged dipeptide would alter the pharmacological properties of OT, [Mpa1]OT, and [Cpa1]OT (OT=oxytocin; Mpa=3-mercaptopropionic acid; Cpa=1-mercaptocyclohexaneacetic

  通常认为，神经下垂体激素类似物的N-末端部分的构象对于它们的药理活性是重要的。在这项工作中，我们决定研究用乙烯桥连的二肽取代位置2和3将如何改变OT，[Mpa1] OT和[Cpa1] OT的药理特性（OT =催产素； Mpa = 3-巯基丙酸酸； Cpa = 1-巯基环己烷乙酸），并研究在AVP，[Mpa1] AVP和[Cpa1] AVP（AVP =精氨酸加压素）的2位掺入的3,3-二苯基-L-丙氨酸残基如何变化化合物的药理特性。接下来的类似物[Val4] AVP，[Mpa1，Val4] AVP和[Cpa1，Val4] AVP在位置3引入了N-苄基-L-丙氨酸。最后一个肽是通过AVP中的Cys1取代在空间上设计的受限制的笨重的对手，α-羟甲基半胱氨酸。测试了所有肽在大鼠中的体外子宫收缩，加压和抗利尿活性。这些测定的结果表明，分子N末端部分的构象自由度的降低对药理活性具有重大影响。
• AMIDE DERIVATIVES AS ROCK INHIBITORS
  申请人：Sawada Kouzo

  公开号：US20090105231A1

  公开（公告）日：2009-04-23

  This invention relates to novel amide derivatives and salts thereof. More particularly, it relates to novel amide derivatives and salts thereof which act as a ROCK inhibitor, to a pharmaceutical composition comprising the same and to a method of using the same therapeutically in the treatment and/or prevention of ROCK-related disease.

  本发明涉及新型酰胺衍生物及其盐。更具体地说，涉及一种作为ROCK抑制剂的新型酰胺衍生物及其盐，以及包含其的制药组合物和在治疗和/或预防ROCK相关疾病方面的治疗方法。
• NOVEL 3-AMIDO-PYRROLO[3,4-C]PYRAZOLE-5(1H,4H,6H) CARBALDEHYDE DERIVATIVES
  申请人：Botrous Iriny

  公开号：US20100249128A1

  公开（公告）日：2010-09-30

  The present invention relates to compounds and pharmaceutically acceptable salts of Formula (I): wherein X, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 are as defined above. The invention further relates to pharmaceutical compositions comprising the compounds and pharmaceutically acceptable salts and to methods of treating diabetes mellitus and its complications (including in particular diabetic retinopathy, nephropathy or neuropathy), cancer, ischemia, inflammation, central nervous system disorders, cardiovascular disease, Alzheimer's disease and dermatological disease pression, viral diseases, inflammatory disorders, or diseases in which the liver is a target organ.

  本发明涉及式（I）的化合物和药学上可接受的盐，其中X，R1，R2，R3，R4，R5，R6，R7和R8如上所定义。本发明还涉及包含该化合物和药学上可接受的盐的制药组合物以及治疗糖尿病及其并发症（尤其是糖尿病视网膜病变、肾病或神经病变）、癌症、缺血、炎症、中枢神经系统疾病、心血管疾病、阿尔茨海默病和皮肤病、病毒性疾病、炎症性疾病或肝脏是靶器官的疾病的治疗方法。
• NOVEL 3-AMIDO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H,6H) CARBALDEHYDE DERIVATIVES
  申请人：Botrous Iriny

  公开号：US20120108588A1

  公开（公告）日：2012-05-03

  The present invention relates to compounds and pharmaceutically acceptable salts of Formula (I): wherein X, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 are as defined above. The invention further relates to pharmaceutical compositions comprising the compounds and pharmaceutically acceptable salts and to methods of treating diabetes mellitus and its complications (including in particular diabetic retinopathy, nephropathy or neuropathy), cancer, ischemia, inflammation, central nervous system disorders, cardiovascular disease, Alzheimer's disease and dermatological disease pression, viral diseases, inflammatory disorders, or diseases in which the liver is a target organ.

  本发明涉及公式（I）的化合物和药学上可接受的盐，其中X，R1，R2，R3，R4，R5，R6，R7和R8如上所定义。本发明还涉及包含该化合物和药学上可接受的盐的制药组合物，以及治疗糖尿病及其并发症（尤其是糖尿病视网膜病变，肾病或神经病变），癌症，缺血，炎症，中枢神经系统疾病，心血管疾病，阿尔茨海默病和皮肤病，病毒性疾病，炎症性疾病或肝脏是靶器官的疾病的治疗方法。